Alkermes plc (ALKS) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $49.27 (-1.47%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 26, 2026 | Douglas Tsao | H.C. Wainwright | $43.00 | -12.7% |
| Oct 28, 2025 | Akash Tewari | Jefferies | $56.00 | +13.7% |
| Oct 23, 2025 | David Amsellem | Piper Sandler | $45.00 | -8.7% |
| Sep 26, 2025 | Alkermes to Outperform | RBC Capital | $44.00 | -10.7% |
| Sep 9, 2025 | Douglas Tsao | H.C. Wainwright | $46.00 | -6.6% |
| Jun 17, 2025 | Ashwani Verma | UBS | $42.00 | -14.7% |
| Dec 5, 2024 | David Amsellem | Piper Sandler | $37.00 | -24.9% |
| Nov 13, 2024 | Vamil Divan | Mizuho Securities | $40.00 | -18.8% |
| Nov 4, 2024 | Paul Matteis | Stifel Nicolaus | $36.00 | -26.9% |
| Oct 24, 2024 | Paul Matteis | Stifel Nicolaus | $25.00 | -49.3% |
| Oct 14, 2024 | Douglas Tsao | H.C. Wainwright | $37.00 | -24.9% |
| Apr 10, 2024 | Akash Tewari | Jefferies | $25.00 | -49.3% |
| Apr 9, 2024 | Vamil Divan | Mizuho Securities | $35.00 | -29.0% |
| Apr 9, 2024 | Akash Tewari | Jefferies | $25.00 | -49.3% |
| Mar 18, 2024 | Joel Beatty | Robert W. Baird | $37.00 | -24.9% |
Top Analysts Covering ALKS
ALKS vs Sector & Market
| Metric | ALKS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.24 | 2.25 | 2.42 |
| Analyst Count | 21 | 8 | 19 |
| Target Upside | +3.0% | +16366.1% | +18.0% |
| P/E Ratio | 54.74 | 2.96 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $453M | $475M | $494M | 5 |
| 2026-12-31 | $475M | $498M | $518M | 5 |
| 2027-03-31 | $402M | $421M | $438M | 5 |
| 2027-06-30 | $445M | $467M | $485M | 5 |
| 2027-09-30 | $447M | $469M | $487M | 5 |
| 2027-12-31 | $455M | $477M | $496M | 5 |
| 2028-12-31 | $2.06B | $2.06B | $2.06B | 11 |
| 2029-12-31 | $2.22B | $2.29B | $2.41B | 5 |
| 2030-12-31 | $2.46B | $2.53B | $2.67B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.04 | $-0.04 | $-0.04 | 1 |
| 2026-12-31 | $-0.00 | $-0.00 | $-0.00 | 1 |
| 2027-03-31 | $-0.14 | $-0.13 | $-0.13 | 1 |
| 2027-06-30 | $0.08 | $0.08 | $0.09 | 1 |
| 2027-09-30 | $0.07 | $0.07 | $0.08 | 1 |
| 2027-12-31 | $0.06 | $0.06 | $0.07 | 1 |
| 2028-12-31 | $-0.25 | $1.30 | $3.70 | 10 |
| 2029-12-31 | $2.13 | $2.21 | $2.37 | 4 |
| 2030-12-31 | $3.11 | $3.23 | $3.46 | 4 |
Frequently Asked Questions
What is the analyst consensus for ALKS?
The consensus among 21 analysts covering Alkermes plc (ALKS) is Buy with an average price target of $52.60.
What is the highest price target for ALKS?
The highest price target for ALKS is $56.00, set by Akash Tewari at Jefferies on 2025-10-28.
What is the lowest price target for ALKS?
The lowest price target for ALKS is $25.00, set by Akash Tewari at Jefferies on 2024-04-09.
How many analysts cover ALKS?
21 analysts have issued ratings for Alkermes plc in the past 12 months.
Is ALKS a buy or sell right now?
Based on 21 analyst ratings, ALKS has a consensus rating of Buy (2.24/5) with a +3.0% upside to the consensus target of $52.60.
What are the earnings estimates for ALKS?
Analysts estimate ALKS will report EPS of $-0.04 for the period ending 2026-09-30, with revenue estimated at $475M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.